Biography
Nicholas Barnabo is counsel in Weil’s Antitrust practice.
He has advised on various high profile, complex and multi-jurisdictional M&A transactions, with a particular focus on cross-border merger control and foreign investment reviews. His experience covers antitrust and regulatory proceedings before the European Commission, EU member states, the UK CMA and various key regulators globally.
Prior to joining Weil, Nick was a senior associate at a global law firm in London and before that practiced as an associate at a leading US firm in Brussels.
He regularly advises private equity firms, sovereign wealth funds and corporations across a wide range of industry sectors.
Representative experience from previous firms includes:
- Brookfield Renewable Partners on its $7.9 billion acquisition of nuclear power plant equipment maker Westinghouse Electric
- Bain Capital on its acquisition of Deltatre
- Brookfield on its $16 billion acquisition of Nielsen
- Brookfield on its €17.5 billion acquisition of Deutsche Telekom AG’s tower business
- Eutelsat on its $3.4 billion combination with OneWeb
- Advising an ad hoc group of secured lenders to the world’s largest regional aircraft lessor, Nordic Aviation Capital, in relation to its restructuring
- Advising Genstar Capital on acquisition of portfolio company Bihr
- PX3 on the acquisition of the filtration division (Filtration) of U.S. headquartered Celeros Flow Technology
- Advent International on the investment in Medius
- BNF Capital Limited on its investment in Rolls-Royce nuclear power Small Modular Reactors
- KPS Capital Partners on merger control and FDI aspects of various transactions
- Generali Group and DZ Bank on merger control aspects of their acquisition of Puerto Venecia Shopping Complex
- DuPont on the conditional approval of the $130 billion merger of equals with The Dow Chemical Company
- DuPont on a business swap with FMC Corporation, exchanging portions of DuPont’s crop protection business for FMC’s health and nutrition business
- TPG Capital and its portfolio company The Warranty Group on merger control aspects of its acquisition by Assurant
- Patheon on merger control aspects of its $7.2 billion acquisition by Thermo Fisher Scientific Inc